Tacrolimus plus low-dose mycophenolate mofetil in renal transplant recipients: Better 2-year graft and patient survival than with a higher mycophenolate mofetil dose

Kocak H., Yakupoglu Ü. , Karatas G., Yavuz A., Gurkan A., Erdogan O., ...Daha Fazla

TRANSPLANTATION PROCEEDINGS, cilt.37, sa.7, ss.3009-3011, 2005 (SCI İndekslerine Giren Dergi) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 37 Konu: 7
  • Basım Tarihi: 2005
  • Doi Numarası: 10.1016/j.transproceed.2005.07.033
  • Sayfa Sayıları: ss.3009-3011


Objectives. Mycophenolate mofetil (MMF) has become more widely prescribed in recent years, but its adverse effects on the gastrointestinal system and bone marrow restrict its use in certain settings. The aim of this study was to compare the demographic features and clinical data for 173 renal transplant recipients who received tacrolimus (TAC) plus 1 g/d MMF (group I, n = 112) versus TAC plus 2 g/d MMF (group II, n = 61 patients) over a 2-year period. Each patient received similar TAC doses.